Company intelligence / Profile preview
Supernus Pharmaceuticals, Inc.
Rockville, Maryland, United Statessupernus.com ↗
- Ownership
- Public · SUPN
- Development stage
- Other
01
Overview
Supernus has multiple marketed products for CNS conditions and several candidates in late-stage development. In February 2025, they received FDA approval for ONAPGO (apomorphine hydrochloride) injection for Parkinson's disease. In January 2025, they received FDA approval for the label for Qelbree (viloxazine extended-release capsules).
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Britannia Pharmaceuticals LimitedZambon S.p.A
04
Financials
- Market cap
- $1.6B
- Total revenue
- $1.2B
- Enterprise value
- $1.8B
Beyond the preview
Go deeper on Supernus Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Supernus Pharmaceuticals, Inc..